Top FDA Officials Warn About Non-Vetted Pharmacogenetic Tests After Latest 23andMe Approval
Executive Summary
A day after 23andMe gained US FDA go-ahead for a DTC genetic test service to inform patients about their ability to metabolize medications, the agency issued a safety communication, paired with a joint statement from device- and drug-center heads, warning consumers against trusting genetic tests that have not been vetted by FDA.
You may also be interested in...
Virgin Group Fund Elevates 23AndMe $3.5Bn IPO
23andMe is teaming up with blank check company VG Acquisition Corp to go public, making the move into personalized health care.
23AndMe To Go Public At $3.5Bn With Sir Richard Branson-Backed SPAC
23andMe is teaming up with blank check company VG Acquisition Corp to go public, making the move into personalized health care.
Petition Argues FDA Has Overstepped In PGx Regulation
A group of manufacturers and clinicians is asking the US agency to allow more discussion between manufacturers, labs and clinicians of how genetic factors could influence drug effectiveness – an area known as pharmacogenomics (PGx). The FDA had previously taken several steps to limit these communications.